QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=C22459D1FC782BBF88AE726AB2ED8519;jsessionid=63DE3311F32126CEC93952F329EA64C4;jsessionid=109AF45423819407DB36B918D39A92B4;jsessionid=D50743515CB50E1A3DCC90C246F0B233;jsessionid=54CF2D5F452A61228D2A989AE3B20244;jsessionid=D613243C7E6A95673D8769AE76CB10C3;jsessionid=CEFCD10C2B7D401AC12C82569F0FBBD3 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=C22459D1FC782BBF88AE726AB2ED8519;jsessionid=63DE3311F32126CEC93952F329EA64C4;jsessionid=109AF45423819407DB36B918D39A92B4;jsessionid=D50743515CB50E1A3DCC90C246F0B233;jsessionid=54CF2D5F452A61228D2A989AE3B20244;jsessionid=D613243C7E6A95673D8769AE76CB10C3;jsessionid=CEFCD10C2B7D401AC12C82569F0FBBD3